STOCK TITAN

Akero Therapeutics Inc - AKRO STOCK NEWS

Welcome to our dedicated news page for Akero Therapeutics (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akero Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akero Therapeutics's position in the market.

Rhea-AI Summary
Akero Therapeutics, Inc. (AKRO) successfully closed a public offering of 12,650,000 shares of common stock at $29.00 per share, raising approximately $366.9 million. The underwriters exercised their option to purchase additional shares, leading to a significant increase in gross proceeds. The offering was managed by top firms like J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
offering
-
Rhea-AI Summary
Akero Therapeutics, Inc. announces positive results from a Phase 2b study on efruxifermin (EFX) in patients with Type 2 diabetes and liver fibrosis. The study shows EFX combined with GLP-1 receptor agonist therapy improves liver health markers, reduces liver fat, and enhances metabolic health, indicating potential for treating patients with MASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
clinical trial
-
Rhea-AI Summary
Akero Therapeutics, Inc. (AKRO) announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at $29.00 per share, aiming to raise $319.0 million. The company has also granted underwriters an option to purchase additional shares. This move is part of Akero's strategy to develop treatments for metabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
offering
Rhea-AI Summary
Akero Therapeutics, Inc. (AKRO) initiates a $300.0 million public offering of common stock, with a 30-day option for an additional $45.0 million. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are the joint book-running managers. The offering is subject to market conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
offering
-
Rhea-AI Summary
Akero Therapeutics (AKRO) releases promising week 96 results from HARMONY study on EFX for pre-cirrhotic MASH patients, showing significant improvements in fibrosis stages and histological endpoints. The 50mg EFX group demonstrated a 75% improvement in fibrosis, a 46% improvement for the 28mg group, and significant improvements in various histological endpoints compared to the placebo group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.72%
Tags
clinical trial
-
Rhea-AI Summary
Akero Therapeutics, Inc. (AKRO) will present clinical data from its HARMONY study after 96 weeks of treatment for pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients. The investor webcast is scheduled for March 4 at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences clinical trial
Rhea-AI Summary
Akero Therapeutics, Inc. reported Q4 and full year financial results for 2023, with significant updates on their Phase 3 SYNCHRONY program and Phase 2b SYMMETRY study. They initiated two Phase 3 studies and reported promising results in the Phase 2b study. Financially, Akero's cash reserves are strong, supporting operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
earnings
-
Rhea-AI Summary
Akero Therapeutics, Inc. (Nasdaq: AKRO) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 09:45 a.m. P.T. in San Francisco, CA. The company is focused on developing transformational treatments for patients with serious metabolic diseases with high unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
conferences
-
Rhea-AI Summary
Akero Therapeutics, Inc. (Nasdaq: AKRO) has reported the initiation of Phase 3 trials for their drug Efruxifermin (EFX) in patients with pre-cirrhotic NASH/MASH and compensated cirrhosis. The company is also planning an End-of-Phase 2 FDA meeting and expects to release the results of the Phase 2b HARMONY study in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
clinical trial
Rhea-AI Summary
Akero Therapeutics, Inc. (Nasdaq: AKRO) reports third quarter financial results and business updates, including progress on Phase 3 SYNCHRONY studies for patients with NASH. The company is encouraged by the clinical development of EFX for pre-cirrhotic and cirrhotic NASH, with screening for the studies actively underway and on track for enrollment by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
earnings
Akero Therapeutics Inc

Nasdaq:AKRO

AKRO Rankings

AKRO Stock Data

1.69B
46.04M
5.92%
94.48%
16.7%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About AKRO

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.